Project Grant K99CA297021
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$141K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
The National Cancer Institute (NCI) awarded a 5-year, $185,693 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Research Institute at Nationwide Children's Hospital (RINCH) in Columbus, Ohio. The grant, titled "A Digital Health Parent Coaching Intervention to Improve Neurodevelopmental Outcomes for Young Childhood Cancer Survivors in Underserved Communities," aims to develop and evaluate a digital health program that provides parent coaching to improve...
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to investigate the mechanisms underlying the increased risk of hematological malignancy (HM) in patients with sickle cell disease, including those who have undergone gene therapy or hematopoietic stem cell transplant. The research aims to determine if oxidative stress-induced DNA damage in...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded Duke University a Project Grant totaling $1,123,468 to conduct a randomized controlled trial of a hybrid-delivered cognitive behavioral symptom management and activity coaching intervention for hematopoietic stem cell transplant patients. The goal is to use mobile health technology to enable these patients to effectively cope with symptoms like fatigue, pain, and distress, in order to improve their physical...
The National Cancer Institute (NCI) awarded a $602,486 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Health Research, Inc., a not-for-profit research organization based in Buffalo, NY. The grant aims to explore the feasibility of targeting retrotransposons, or mobile genetic elements, as a novel approach to treating refractory pediatric cancers, with a primary focus on high-risk neuroblastoma. The project seeks to comprehensively characterize retrotransposon activity...
This National Cancer Institute (NCI) Project Grant award under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $227,941 to The Washington University in St. Louis to develop and pilot an electronic health record (EHR)-based communication tool called the "Cancer Care Companion." Awarded on April 12, 2025, this 2-year project aims to engage parents of children with cancer to co-develop the EHR tool, which will adapt the existing Epic MyChart Care Companion platform...
This Project Grant award, totaling $1,220,394.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research Federal Grant Program (CFDA 93.395). The primary objective is to conduct a comprehensive, multi-disciplinary study exploring the molecular pathogenesis and clinical characterization of acute and chronic neurotoxicity associated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. The research plan involves investigating changes...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) totaling $599,339 aims to conduct a randomized trial evaluating the efficacy of a multidisciplinary telehealth intervention (HORIZONS) compared to usual care for improving quality of life, psychological distress, symptoms, coping, and self-efficacy in hematopoietic stem cell transplant survivors with chronic graft-versus-host disease. The study will be conducted at the University of...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to determine the feasibility of implementing a randomized controlled trial to evaluate a virtual, music-based relaxation intervention for reducing anxiety in adolescent and young adult (AYA) cancer survivors. The primary aim is to assess the feasibility of delivering an 8-week, virtual "Tailored, Music-Based Relaxation (TIMBRE)" intervention to AYA cancer survivors...
This $225,101 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Baylor College of Medicine to investigate how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The key objectives are to: 1) determine how MYCN rewires T cell metabolism to promote immune suppression, and 2) elucidate how MYCN-induced lipogenesis contributes to a suppressive tumor immune microenvironment. This 2-year...